You are on page 1of 4

Treatment in Psychiatry

Treatment in Psychiatry begins with a hypothetical case illustrating a problem in current clinical practice. The authors
review current data on prevalence, diagnosis, pathophysiology, and treatment. The article concludes with the authors'
treatment recommendations for cases like the one presented.

Psychotic and Manic-like Symptoms During Stimulant


Treatment of Attention Deficit Hyperactivity Disorder

Randal G. Ross, M.D. Stimulantsparticularly methylphenidate and am-


phetaminesare a critical first-line option in the treat-
ment of attention deficit hyperactivity disorder (ADHD) in
children and adolescents (1). The potential for stimulants
to induce psychosis-like or manic-like symptoms in chil-
A boy 6 years 9 months of age was dren has been known for at least 35 years, since Lucas and
brought by his mother to a child psychia- Weiss (2) reported on three cases of methylphenidate hal-
trist for difficulties with sustained atten- lucinosis. The terms hallucinosis and toxicosis are of-
tion, distraction, careless errors, poor lis- ten used to distinguish the transient symptoms associated
tening, difficulty following instructions, with stimulant use from the longer-lasting symptoms of
difficulty with organization, frequently schizophrenia and bipolar disorder. The U.S. Food and
misplaced items, and forgetfulness in Drug Administration (FDA), while assessing the signifi-
daily activities. He had no history of im- cance of rare risks in ADHD treatments, recently asked its
pulsive or hyperactive behavior, mood Pediatric Advisory Committee to review reports of stimu-
symptoms, or tics. He had been born af- lant-associated psychotic-like and manic-like symptoms.
ter an unremarkable full-term pregnancy The committee was to comment on the import of the rela-
to a 43-year-old mother who did not use tionship between therapeutic uses of stimulants and psy-
alcohol or drugs during pregnancy. The chosis or mania; whether the benefits of stimulants justify
child was delivered by cesarean section a risk of psychosis or mania; and whether information
after failure to progress in labor and had about risk was adequately relayed to the public (3). This
a normal postnatal course. His family his- case raises the clinical issues of diagnosis and treatment of
tory was negative for mood disorders, psychotic-like and manic-like symptoms arising during
psychosis, obsessive-compulsive symp- stimulant use in children with ADHD.
toms, or tics.
Stimulant-Induced Psychosis or Mania
Several months later, the symptoms had Stimulant medications at high doses can induce symp-
been confirmed in the home, school, and toms of mania and psychosis that are highly similar to
tutoring environments. The patient, then those of bipolar or schizophrenic illnesses (4, 5). These
7 years 4 months of age, was started on symptoms generally resolve within 2 days after discontinu-
methylphenidate, and he showed a clear ation of the stimulant, although symptoms lasting 6 days
dose-response effect. An extended-re- or longer have been reported (5). The pharmacologic ef-
lease formulation of methylphenidate fects of stimulants include the ability to increase dopamin-
was then prescribed, and the dose was ergic and noradrenergic neurotransmission. Observations
gradually increased over a 2-month pe- of clinical similarities between schizophrenia and stimu-
riod to 40 mg per day. At this dose, the lant-induced psychosis provided initial evidence support-
patient had a strongly beneficial re- ing the dopaminergic theory of schizophrenia (6), and
sponse, and the only side effect noted more recent observations suggest that the psychosis seen
was mild anorexia. Eight months later, at in methamphetamine abusers reflects an interaction be-
8 years 3 months of age, after a flu-like tween substance abuse and an underlying vulnerability to
illness, he developed new symptoms, psychosis (7). Thus, symptoms induced by high doses of
which included complaints of hearing stimulants may provide a window into understanding
voices and seeing adults when no one some forms of psychosis and mania.
was present, a desire to throw himself
down the stairs, high levels of anxiety,
Therapeutic Doses of Stimulants
tearfulness at school, an unwillingness to
leave his mothers side, and irritability. Anecdotal reports (8) have been published on the rela-
tion between therapeutic doses of stimulants and mania or
psychosis, but the topic has not been closely examined. Re-
cently, the FDA reviewed several pharmaceutical com-

Am J Psychiatry 163:7, July 2006 ajp.psychiatryonline.org 1149


TREATMENT IN PSYCHIATRY

pany-sponsored trials of methylphenidate formulations, ulant; all five of these patients were rediagnosed as hav-
amphetamine salts, modafinil, and atomoxetine (912). ing either bipolar disorder or schizophrenia.
Combining across stimulant medications, during double- Predicting who is at risk of stimulant toxicosis is prob-
blind, placebo-controlled trials, placebo was not associ- lematic. The case reports are notable for a broad range in
ated with any toxicosis events in 3,990 subjects with a com- patients ages (217 years), a variety of medications, a wide
bined duration of treatment of over 425 years. For thera- range for duration of exposure, the symptoms reported,
peutic doses of active medication, there were 13 reports of and symptom severity. The cases are similar only in the
toxicosis in 5,717 subjects with a combined treatment du- generally brief duration of stimulant-induced symptoms:
ration of over 800 years. In open-label trials, stimulants recovery typically occurs within 2 daysand almost al-
were associated with 45 reports of toxicosis in 15,999 sub- ways within 7 daysof discontinuing the medication or
jects with a combined treatment dura- lowering the dose. Moreover, with dis-
tion of almost 9,400 years. Although continuation of the stimulant, the re-
there are methodological problems in These numbers emergence of ADHD symptoms is typ-
summing across stimulant medica-
tions and across studies that may have
suggest. . . that toxicosis ically rapid. Family history is unlikely
to be a useful clinical predictor. Even
different sensitivities for identifying will occur in among children with a first-degree rel-
psychotic-like and manic-like symp- ative with schizophrenia or bipolar
toms, these numbers suggest as a pre-
approximately 0.25% disorder, attentional dysfunction
liminary estimate that toxicosis will of children treated with without later onset of psychosis or
occur in approximately 0.25% of chil- mania is more common than atten-
dren treated with stimulants, or about
stimulants, or tional dysfunction preceding psycho-
1 in 400a proportion suggesting an about 1 in 400. sis or mania (21, 22). Moreover, chil-
infrequent but not rare effect of thera- dren with the more common forms of
peutic dosing. pediatric bipolar disorder may benefit
The severity and duration of stimulant-induced toxico- from stimulant medication (23). In short, stimulant-in-
sis were also examined. In the FDA studies, a broad array duced toxicosis appears to be truly idiosyncratican im-
of search terms was used to identify cases of possible toxi- portant but infrequent and unpredictable side effect of
cosis in pharmaceutical company-sponsored trials. Al- stimulant treatment.
though this approach is highly sensitive in identifying
cases of toxicosis, it also identifies cases with less specific A Marker of Vulnerability
and less severe symptoms, such as anxiety, social with-
Most cases of stimulant toxicosis resolve with discontin-
drawal, aggression, and irritability. When all of these cases
uation of the stimulant. However, attentional dysfunction,
were considered as a group of psychiatric adverse
whether measured by cognitive testing (24) or by ADHD-
events, the most common outcomes were listed as not
like clinical symptoms (25), is a common premorbid pre-
reported or not available. Thus, while the FDA reported
sentation for children who later manifest schizophrenia or
that, depending on the stimulant, 33%58% of cases of
bipolar disorder. Retrospective data from patients with
stimulant-induced psychiatric adverse events resolved
schizophrenia or bipolar disorders document high rates of
with discontinuation of the drug, the use of broad search
childhood stimulant usegenerally higher even than
criteria and the lack of outcome data make these numbers
other groups with attentional dysfunction (26) and histo-
difficult to interpret.
ries of stimulant-associated adverse behavioral effects
An alternative approach to examining adverse out-
(27). In these patients, a history of stimulant use is also as-
come data was used in a contribution (13) to the recent
sociated with an earlier age at onset (28) and a more severe
national discussion on the relationship between antide-
course of illness during hospitalization (29). Stimulant ex-
pressants and suicidal thoughts. Individually identified
posure in vulnerable individuals may hasten the onset or
cases in the FDA database were subjected to expert re-
worsen the course of bipolar or schizophrenic illnesses
view, focusing on particularly clear cases. In an attempt
(26, 30). Thus, while stimulants are clearly beneficial for
to follow this approach, I examined case reports from
the vast majority of children with ADHD, there may be a
FDA publications (912) and the literature (2, 1420) in
small subgroup for whom the medications worsen the
which descriptive summaries were presented of psy-
long-term course of other illnesses. Research aimed at de-
chotic-like or manic-like symptoms occurring during
termining whether such a subgroup exists and how to
stimulant treatment, in which stimulant treatment was
identify it is warranted.
discontinued or reduced, and in which outcome was
discussed. Data were available for 60 cases. In 55 cases
(92%), the psychotic-like or mania-like symptoms re-
Recommendations
solved, and hence these cases might be better termed Stimulants are highly beneficial for children with ADHD
stimulant toxicosis than psychosis or mania. In the re- and are a valuable component of the treatment armamen-
maining five cases (8%), psychotic symptoms either tarium. However, therapeutic doses of stimulants can
continued or recurred after discontinuation of the stim- cause manic-like or psychotic-like symptoms in a small

1150 ajp.psychiatryonline.org Am J Psychiatry 163:7, July 2006


TREATMENT IN PSYCHIATRY

proportion of treated children. These symptoms can in- week later, and the symptoms did not re-
clude euphoria, grandiosity, paranoid delusions, confu- cur. The patient, now 11 years 4 months
sion, hallucinations, and increased aggression. Other than of age, has been maintained on meth-
a history of sustained psychosis or clear sustained mania, ylphenidate since that time. His atten-
there are no good predictors of such responses. The symp- tional dysfunction remains markedly re-
toms can occur with the first dose or after months of stable duced, and the psychotic-like symptoms
treatment. Thus, caregivers need to be educated about have not recurred.
such side effects. The majority of manic-like and psy-
chotic-like reactions present no immediate danger. How-
ever, when stimulant toxicosis is identified, patients must
be evaluated for symptoms that increase the risk of imme-
diate harm. These include suicidal ideation, command Received April 8, 2006; revision received April 18, 2006; accepted
hallucinations, increased aggressive urges, and impaired April 24, 2006. From the Department of Psychiatry, University of Col-
orado at Denver and Health Sciences Center, Denver. Address corre-
judgment. If symptoms are not severe or the child is spondence and reprint requests to Dr. Ross, Department of Psychia-
young, increased or continuous direct parental supervi- t r y, B o x C 2 6 8 - 3 1 , 4 2 0 0 E . 9 t h A v e . , D e n v e r, C O 8 0 2 6 2 ;
sion is indicated; if symptoms are severe and the child is randy.ross@uchsc.edu (e-mail).
Supported by NIH grants MH-056539 and MH-068582.
older, urgent or emergent evaluation by an experienced
Dr. Ross owns shares of Johnson & Johnson stock. Dr. Freedman has
mental health professional is warranted. Discontinuation reviewed this article and found no evidence of influence from this re-
of the stimulant during the acute toxicosis is generally the lationship.
best approach. After discontinuation of the stimulant,
stimulant toxicosis generally resolves within 2448 hours
and almost always within 7 days. Currently, there is no References
strong evidence that stimulant toxicosis predicts later risk 1. Rappley MD: Attention deficit-hyperactivity disorder. N Engl J
of bipolar or schizophrenic illnesses, and antipsychotic Med 2005; 352:165173
and mood-stabilizing medications have significant side 2. Lucas AR, Weiss M: Methylphenidate hallucinosis. JAMA 1971;
effects. Thus, sustained antipsychotic or mood stabilizer 217:10791081
treatment of a child based solely on a history of stimulant 3. Pediatric Advisory Committee Meeting, March 22, 2006, Draft
Questions for the Committee. US Food and Drug Administra-
toxicosis is generally not warranted. Once the acute psy-
tion, 2006. Available at www.fda.gov/ohrms/dockets/ac/06/
chotic-like or manic-like symptoms resolve, the discontin- questions/2006-4210q_DRAFT-Questions.pdf
uation of stimulants is almost always associated with a re- 4. Snyder SH: Amphetamine psychosis: a model schizophrenia
turn of the symptoms that led to stimulant treatments. At mediated by catecholamines. Am J Psychiatry 1973; 130:6167
that point, treatment strategies often must be reconsid- 5. Bell DS: The experimental reproduction of amphetamine psy-
ered. Given the highly beneficial effects of stimulants for chosis. Arch Gen Psychiatry 1973; 29:3540
many patients with ADHD (31), even in cases in which in- 6. Meltzer HY, Stahl SM: The dopamine hypothesis of schizophre-
nia: a review. Schizophr Bull 1976; 2:1976
attention is the primary symptom (32, 33), rechallenge
7. Chen CK, Lin SK, Sham PC, Ball D, Loh el-W, Murray RM: Morbid
with a stimulant medication is often appropriate, al- risk for psychiatric disorder among the relatives of metham-
though close follow-up to assess for any return of stimu- phetamine users with and without psychosis. Am J Med Genet
lant toxicosis is indicated. The majority of children who B Neuropsychiatr Genet 2005; 136:8791
experience brief psychotic-like or manic-like symptoms 8. Hellander M: Medication-induced mania: ethical issues and
when taking therapeutic doses of a stimulant will not de- the need for more research. J Child Adolesc Psychopharmacol
velop a recurrent psychotic illness, although evaluation 2003; 13:199
9. Gelperin K, Phelan K: Psychiatric adverse events associated
for comorbid or premorbid symptoms by clinicians with
with drug treatment of ADHD: review of postmarketing safety
experience in treating mania or psychosis in young chil- data. FDA Report PID D050243. US Food and Drug Administra-
dren is appropriate. tion, March 3, 2006. Available at www.fda.gov/ohrms/dockets/
ac/06/briefing/2006-4210b_11_01_AdverseEvents.pdf
10. Mosholder A: Psychiatric adverse events in clinical trials of
drugs for ADHD. FDA Report PID D060163. US Food and Drug
A dm i n i s t r a t io n , M a rc h 3, 2 0 06 . Av a i la b le a t h t t p : //
For this patient, the dose of methylpheni- w w w. f d a . g o v / o h r m s / d o c k e t s / a c / 0 6 / b r i e f i n g / 2 0 0 6 -
date was reduced to 20 mg per day, and 4210b_10_01_Mosholder.pdf
over the following 3 weeks the psychotic- 11. Phelan K: Summary of psychiatric and neurological adverse
like symptoms gradually resolved. Sev- events from June 2005 1-year post pediatric exclusivity reviews
eral months later, at 9 years 0 months of of Concerta and other methylphenidate products. US Food and
Drug Administration, 2006. Available at www.fda.gov/ohrms/
age, again after a flu-like illness, he de-
dockets/ac/06/briefing/2006-4210b_09_01_Methsummary.pdf
veloped a milder version of the same
12. Phelan KM: One year post-pediatric exclusivity postmarketing
symptoms. During this episode, meth- adverse event review: Adderall XR. FDA Report PID D040761.
ylphenidate was discontinued, and all US Food and Drug Administration, Jan 5, 2006. Available at
symptoms resolved within 36 hours. w w w. f d a . g o v / o h r m s / d o c k e t s / a c / 0 6 / b r i e f i n g / 2 0 0 6 -
Methylphenidate was reintroduced 1 4210b_05_02_AdderallSafetyReview.pdf

Am J Psychiatry 163:7, July 2006 ajp.psychiatryonline.org 1151


TREATMENT IN PSYCHIATRY

13. Hammad TA, Laughren T, Racoosin J: Suicidality in pediatric 24. Erlenmeyer-Kimling L, Rock D, Roberts SA, Janal M, Kesten-
patients treated with antidepressant drugs. Arch Gen Psychia- baum C, Cornblatt B, Adamo UH, Gottesman II: Attention,
try 2006; 63:332339 memory, and motor skills as childhood predictors of schizo-
14. Bloom AS, Russell LJ, Weisskopf B, Blackerby JL: Methylpheni- phrenia-related psychoses: the New York High-Risk Project. Am
date-induced delusional disorder in a child with attention def- J Psychiatry 2000; 157:14161422
icit disorder with hyperactivity. J Am Acad Child Adolesc Psychi- 25. Marcus J, Hans SL, Auerback JG, Mirsky AF, Aubrey A: Review of
atry 1988; 27:8889 the NIMH Israeli Kibbutz-City Study and the Jerusalem Infant
15. Surles LK, May HJ, Garry JP: Adderall-induced psychosis in an Development Study. Schizophr Bull 1987; 13:425438
adolescent. J Am Board Fam Pract 2002; 15:498500
26. Schaeffer J, Ross RG: Childhood-onset schizophrenia: premor-
16. Young JG: Methylphenidate-induced hallucinosis: case histo-
bid and prodromal diagnosis and treatment histories. J Am
ries and possible mechanisms of action. J Dev Behav Pediatr
Acad Child Adolesc Psychiatry 2002; 41:538545
1981; 2:3538
17. Koehler-Troy C, Strober M, Malenbaum R: Methylphenidate-in- 27. Faedda GL, Baldessarini RJ, Blovinsky IP, Austin NB: Treatment-
duced mania in a prepubertal child. J Clin Psychiatry 1986; 47: emergent mania in pediatric bipolar disorder: a retrospective
566567 case review. J Affect Disord 2004; 82:149158
18. Calello DP, Osterhoudt KC: Acute psychosis associated with 28. DelBello MP, Soutullo CA, Hendricks W, Niemeier RT, McElroy
therapeutic use of dextroamphetamine. Pediatrics 2004; 113: SL, Strakowski SM: Prior stimulant treatment in adolescents
1466 with bipolar disorder: association with age at onset. Bipolar
19. Gillberg C, Melander H, von Knorring AL, Janois LO, Thernlund Disord 2001; 3:5357
G, Hagglof B, Eidevall-Wallin L, Gustafsson P, Kopp S: Long-term 29. Soutullo CA, DelBello MP, Ochsner BS, McElroy SL, Taylor SA,
stimulant treatment of children with attention-deficit hyperac- Strakowski SM, Keck PE Jr: Severity of bipolarity in hospitalized
tivity symptoms. Arch Gen Psychiatry 1997; 54:857864 manic adolescents with history of stimulant or antidepressant
20. Cherland E, Fitzpatrick R: Psychotic side effects of psychostim- treatment. J Affect Disord 2002; 70:323327
ulants: a 5-year review. Can J Psychiatry 1999; 44:811813 30. Reichart CG, Nolen WA: Earlier onset of bipolar disorder in chil-
21. Faraone SV, Biederman J, Mennin D, Wozniak J, Spencer T: At- dren by antidepressants or stimulants? an hypothesis. J Affect
tention-deficit hyperactivity disorder with bipolar disorder: a Disord 2004; 78:8184
familial subtype? J Am Acad Child Adolesc Psychiatry 1997; 36:
31. Jensen PS, Arnold LE, Richters JE, Severe JB, Vereen D, Vitiello B:
13781387
A 14-month randomized clinical trial of treatment strategies
22. Faraone SV, Biederman J, Mennin D, Russell R: Bipolar and an-
for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry
tisocial disorders among relatives of ADHD children: parsing fa-
1999; 56:10731086
milial subtypes of illness. Am J Med Genet 1998; 81:108116
23. Galanter CA, Carlson GA, Jensen PS, Greenhill LL, Davies M, Li W, 32. Weiss M, Worling D, Wasdell M: A chart review study of the in-
Chuang SZ, Elliott GR, Arnold LE, March JS, Hechtman L, Pel- attentive and combined types of ADHD. J Atten Disord 2003; 7:
ham WE, Swanson JM: Response to methylphenidate in chil- 19
dren with attention deficit hyperactivity disorder and manic 33. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl
symptoms in the Multimodal Treatment Study of Children With PL, Black DO, Seymour KE, Newcorn JH: A dose-response study
Attention Deficit Hyperactivity Disorder titration trial. J Child of OROS methylphenidate in children with attention-deficit/hy-
Adolesc Psychopharmacol 2003; 13:123136 peractivity disorder. Pediatrics 2003; 112:e404

1152 ajp.psychiatryonline.org Am J Psychiatry 163:7, July 2006